Searching News Database: Alzheimer's disease
Your search returned too many results! The most recent 500 items are shown below:
HSMN NewsFeed - 9 Sep 2024
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
Lilly appoints Lucas Montarce as executive vice president and chief financial officer
HSMN NewsFeed - 26 Aug 2024
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
HSMN NewsFeed - 24 Jul 2024
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
HSMN NewsFeed - 8 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
HSMN NewsFeed - 14 Feb 2024
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
Dr. Lisa Johnson-Pratt Joins Aspen Neuroscience as Senior Vice President, Therapeutic Program Lead
HSMN NewsFeed - 4 Jan 2024
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect(TM)
Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect(TM)
HSMN NewsFeed - 18 Dec 2023
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
NeuExcell's AAV Gene Therapy for Malignant Glioma Granted Orphan Drug Designation by FDA
HSMN NewsFeed - 11 Oct 2023
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
Labcorp Launches New Test to Accelerate Path to Diagnosis of Alzheimer's Disease
HSMN NewsFeed - 18 Nov 2022
Synaptogenix Announces $15 Million Private Placement with Existing Investors
Synaptogenix Announces $15 Million Private Placement with Existing Investors
HSMN NewsFeed - 27 Jul 2022
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership
HSMN NewsFeed - 11 Jul 2022
DiamiR Biosciences Appoints Alidad Mireskandari, Ph.D., MBA, as Chief Executive Officer
DiamiR Biosciences Appoints Alidad Mireskandari, Ph.D., MBA, as Chief Executive Officer
HSMN NewsFeed - 20 Apr 2022
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
AbbVie terminates collaboration with BioArctic on alpha-synuclein portfolio
HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
HSMN NewsFeed - 8 Dec 2021
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
HSMN NewsFeed - 3 Jun 2021
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
vasopharm GmbH Announces Results of the NOSTRA III Traumatic Brain Injury Phase III Study
HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
HSMN NewsFeed - 2 Sep 2020
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
NeuroBo Pharmaceuticals Appoints Douglas J. Swirsky to the Board of Directors
HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
HSMN NewsFeed - 3 Feb 2020
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
Eisai Inc. Expands Leadership Team in the US with the Appointment of Two Key Leaders
HSMN NewsFeed - 30 Oct 2019
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
Biogen and Alkermes Announce FDA Approval of VUMERITY(TM) (diroximel fumarate) for Multiple Sclerosis
HSMN NewsFeed - 1 May 2019
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
Athira Pharma Announces Appointment of Dr. Hans J. Moebius as Chief Medical Officer
HSMN NewsFeed - 1 Nov 2018
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
Chris Cargill Appointed Executive Vice President and Chief Financial Officer of Sosei
HSMN NewsFeed - 23 Aug 2018
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
E-Scape Bio Appoints Biopharma Industry Veteran Julie Anne Smith As President and Chief Executive Officer
HSMN NewsFeed - 17 Jul 2018
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
Spruce Biosciences Appoints David Moriarty, Ph.D., as Vice President of Development Operations
HSMN NewsFeed - 9 Jul 2018
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
Mylan Adds to Central Nervous System Portfolio With Launch of Generic Exelon(R) Patch
HSMN NewsFeed - 12 Jun 2018
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 18 May 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
HSMN NewsFeed - 12 Apr 2018
FDA Permits Marketing of IDx-DR for Automated Detection of Diabetic Retinopathy in Primary Care
FDA Permits Marketing of IDx-DR for Automated Detection of Diabetic Retinopathy in Primary Care
HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
HSMN NewsFeed - 12 Jul 2017
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
E-Scape Bio Series A Extension Brings Total Round to $63 Million to Fund Neurodegenerative Disease Pipeline
HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
HSMN NewsFeed - 11 Apr 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago(R) (safinamide) in Canada
HSMN NewsFeed - 9 Dec 2016
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
Lilly and AstraZeneca to Develop Second Potentially Disease-Modifying Treatment for Alzheimer's Disease
HSMN NewsFeed - 28 Oct 2016
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
Alzheimer's Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO
HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
HSMN NewsFeed - 27 Jul 2016
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor
HSMN NewsFeed - 21 Jul 2016
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
ProMIS Neurosciences Announces Appointment of Dr. Johanne Kaplan as Chief Development Officer
HSMN NewsFeed - 21 Jun 2016
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
Neurotrope Appoints Paula T. Trzepacz, M.D. as Executive Vice President and Chief Medical Officer
HSMN NewsFeed - 12 May 2016
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
Accera Completes Enrollment of Phase 3 NOURISH AD Study of AC-1204 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 7 Mar 2016
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
Avant Diagnostics and Amarantus Diagnostics to Combine Operations With Theranostics Health
HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
HSMN NewsFeed - 21 Oct 2015
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
Head Janssen Neuroscientist Appointed to Scientific Advisory Board of Global Dementia Discovery Fund
HSMN NewsFeed - 3 Sep 2014
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
Voyager Therapeutics Appoints Steven Paul, M.D., to Chief Executive Officer
HSMN NewsFeed - 23 Jun 2014
Barry Lederman Appointed Vice President and Chief Financial Officer of Eisai Inc.
Barry Lederman Appointed Vice President and Chief Financial Officer of Eisai Inc.
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 8 May 2014
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors
HSMN NewsFeed - 18 Feb 2014
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction
HSMN NewsFeed - 7 Jan 2014
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
Cortice Biosciences Announces the Appointment of George Farmer, Ph.D. as Chief Executive Officer
HSMN NewsFeed - 16 Dec 2013
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
Neurotrope, Inc., Appoints James Gottlieb to the Company's Board of Directors
HSMN NewsFeed - 16 Dec 2013
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
Premier Biomedical Secures $5 Million Equity Funding From Kodiak Capital Group, LLC
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 8 Aug 2013
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
HSMN NewsFeed - 7 May 2013
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer's Disease
HSMN NewsFeed - 15 Nov 2012
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
Targacept Appoints Stephen A. Hill, M.D., President and Chief Executive Officer
HSMN NewsFeed - 14 Nov 2012
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
StemGenex(TM) on the Forefront of Adult Stem Cell-Based Therapy for Alzheimer's
HSMN NewsFeed - 16 Oct 2012
BioAdvance Expands Team to Support Portfolio Companies and New Investments
BioAdvance Expands Team to Support Portfolio Companies and New Investments
HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
HSMN NewsFeed - 16 Feb 2012
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
Mnemosyne Pharmaceuticals, Inc. Completes $5.4 Million Series A Round to Support Drug Discovery Programs
HSMN NewsFeed - 10 Dec 2011
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
Transition Therapeutics Announces the Departure of Its President and Chief Financial Officer
HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
HSMN NewsFeed - 16 Aug 2011
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
NeuroLogica Corporation Receives CE Mark for Its Portable, High-Resolution SPECT Camera, the inSPira HD(TM)
HSMN NewsFeed - 9 May 2011
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
FDA Grants Orphan Drug Designation for Mithridion's MCD-386CR to Treat Progressive Supranuclear Palsy
HSMN NewsFeed - 12 Apr 2011
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
DARA BioSciences Reports That SurgiVision Has Completed a Commercial Alliance With Brainlab AG
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 11 Apr 2011
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
Pfizer and Medivation Announce Results From Phase 3 Horizon Trial of Dimebon in Huntington Disease
HSMN NewsFeed - 24 Mar 2011
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
HSMN NewsFeed - 8 Feb 2011
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
Positron’s Attrius(R) PET Scanner Seeks Market Expansion into Neurologic Imaging
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 19 Jan 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
HSMN NewsFeed - 14 Jan 2011
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease
HSMN NewsFeed - 16 Sep 2010
FluoroPharma Inc. Appoints Mr. Thijs Spoor as Chief Executive Officer and Director
FluoroPharma Inc. Appoints Mr. Thijs Spoor as Chief Executive Officer and Director
HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
HSMN NewsFeed - 16 Aug 2010
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
Curaxis Pharmaceutical Corp Elects Dr. Bert A. Spilker to Board of Directors
HSMN NewsFeed - 11 Aug 2010
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
Alectos Therapeutics Announces Collaboration With Merck to Develop Drugs for Alzheimer's Disease
HSMN NewsFeed - 13 Jul 2010
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.
HSMN NewsFeed - 8 Mar 2010
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
Afraxis Appoints Chief Scientific Officer and Vice President, Corporate Development
HSMN NewsFeed - 9 Feb 2010
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test
HSMN NewsFeed - 9 Feb 2010
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
Adeona Appoints James S. Kuo, M.D., M.B.A., as Chairman, CEO and President
HSMN NewsFeed - 17 Dec 2009
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
HSMN NewsFeed - 1 Dec 2009
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
DiaMedica Proposes to Expand Into Neurological and Other Disorders Through Acquisition of Sanomune
HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
HSMN NewsFeed - 30 Jul 2009
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
HSMN NewsFeed - 18 Mar 2009
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
Power3 Medical 'On-Track and On-Plan' to Commercialize Diagnostic Blood Tests
HSMN NewsFeed - 10 Mar 2009
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
Revolutionary Genetic Test Now Available for Age-Related Macular Degeneration
HSMN NewsFeed - 6 Feb 2009
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
deCODE Breakthrough in Thyroid Cancer May Enable More Targeted Risk Assessment and Earlier Intervention
HSMN NewsFeed - 4 Feb 2009
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
HSMN NewsFeed - 8 Jan 2009
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
Satori Pharmaceuticals Raises $22M; Names Former Senior Pfizer Executive as CEO
HSMN NewsFeed - 16 Dec 2008
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
Watson Pharmaceuticals Receives FDA Approval for Generic Razadyne(R) ER Capsules
HSMN NewsFeed - 28 Oct 2008
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
MDS Pharma Services Takes Novel Steps to Recruit Patients for Alzheimer’s Disease Study
HSMN NewsFeed - 17 Sep 2008
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
Memory Pharmaceuticals Realigns Workforce to Support Development Programs
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 30 Jul 2008
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
HSMN NewsFeed - 24 Jul 2008
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
HSMN NewsFeed - 29 May 2008
Aspect Medical Systems Announces U.S. Sales Force Expansion Plan and Reaffirms Q2 Financial Guidance
Aspect Medical Systems Announces U.S. Sales Force Expansion Plan and Reaffirms Q2 Financial Guidance
HSMN NewsFeed - 14 May 2008
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
HSMN NewsFeed - 31 Mar 2008
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease
HSMN NewsFeed - 13 Mar 2008
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 12 Mar 2008
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
HSMN NewsFeed - 20 Feb 2008
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
HSMN NewsFeed - 31 Jan 2008
Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments
Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments
HSMN NewsFeed - 29 Jan 2008
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
Pipex Pharmaceuticals Provides Update on COPREXA (Oral Tetrathiomolybdate) New Drug Application
HSMN NewsFeed - 28 Dec 2007
Transition Therapeutics Announces Appointment of Vice-President of Business Development
Transition Therapeutics Announces Appointment of Vice-President of Business Development
HSMN NewsFeed - 27 Dec 2007
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
U.S. District Court Decision About Eisai's Legal Action Over Aricept ODT(R) ANDA Filing
HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
HSMN NewsFeed - 8 Nov 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
Neurochem announces important initiatives to provide medical and health benefits to patients
HSMN NewsFeed - 22 Oct 2007
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 10 Oct 2007
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
HSMN NewsFeed - 25 Sep 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
HSMN NewsFeed - 28 Aug 2007
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
Neuro-Hitech Announces the Appointment of Dr. Gary Shearman as President and Chief Executive Officer
HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
HSMN NewsFeed - 14 Aug 2007
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
HSMN NewsFeed - 8 Aug 2007
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
Medivation Names Robert Elfont, M.D., Ph.D., Vice President of Clinical Development
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 24 Jul 2007
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
Icagen Announces Filing of IND for ICA-105665, a Novel Compound for the Treatment of Epilepsy
HSMN NewsFeed - 24 Jul 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
HSMN NewsFeed - 27 Jun 2007
Aspect Medical Systems Receives FDA Clearance for BIS View(TM) Monitoring System
Aspect Medical Systems Receives FDA Clearance for BIS View(TM) Monitoring System
HSMN NewsFeed - 22 Jun 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
HSMN NewsFeed - 21 Jun 2007
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
LAB International licenses Fentanyl TAIFUN(R) to Janssen Pharmaceutica NV for Europe
HSMN NewsFeed - 19 Jun 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
HSMN NewsFeed - 18 Jun 2007
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
NeuroLogica Supports NFL Summit to Review Policies on Concussion and Head Injury
HSMN NewsFeed - 18 Jun 2007
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
CoMentis Receives FDA Clearance to Begin Human Clinical Trials for Its Disease-Modifying Alzheimer's Therapy
HSMN NewsFeed - 4 Jun 2007
Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors
Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors
HSMN NewsFeed - 31 May 2007
Abiomed Appoints Eric A. Rose, M.D., a Leader in Circulatory Care, to Its Board of Directors
Abiomed Appoints Eric A. Rose, M.D., a Leader in Circulatory Care, to Its Board of Directors
HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
HSMN NewsFeed - 29 May 2007
Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program
Boston Life Sciences Names Scientific and Clinical Advisors for Nerve Repair Program
HSMN NewsFeed - 21 May 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
HSMN NewsFeed - 21 May 2007
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease
HSMN NewsFeed - 20 May 2007
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
HSMN NewsFeed - 17 May 2007
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
DURECT Provides an Update to the Memryte(TM) Program Under Development by Voyager Pharmaceutical Corp
HSMN NewsFeed - 17 May 2007
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
Cortex's AMPAKINE(R) Drug May Offer New Hope for Memory Problems Associated with Huntington's Disease
HSMN NewsFeed - 2 May 2007
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
HSMN NewsFeed - 1 May 2007
Daniel J. Moore Appointed President and Chief Executive Officer of Cyberonics
Daniel J. Moore Appointed President and Chief Executive Officer of Cyberonics
HSMN NewsFeed - 23 Apr 2007
Prana Expands Senior Management Team with Appointment of Two US-based Pharmaceutical Executives
Prana Expands Senior Management Team with Appointment of Two US-based Pharmaceutical Executives
HSMN NewsFeed - 13 Apr 2007
Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinson's Disease
Ceregene Enrolling Patients for Phase 2 Clinical Trial of Parkinson's Disease
HSMN NewsFeed - 12 Apr 2007
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
HSMN NewsFeed - 10 Apr 2007
New BIO Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs
New BIO Study Confirms Innovative Therapies Will Have Minimal Impact on Healthcare Costs
HSMN NewsFeed - 3 Apr 2007
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
FDA Grants Fast Track Designation to Alzheimer's Disease Drug Candidate AZD-103/ELND005
HSMN NewsFeed - 22 Mar 2007
Sanarus Medical, Inc. Appoints John F. Howe as President and Chief Executive Officer
Sanarus Medical, Inc. Appoints John F. Howe as President and Chief Executive Officer
HSMN NewsFeed - 20 Mar 2007
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
Myriad Genetics Completes Enrollment in Second Phase 3 Clinical Trial of Flurizan(TM) in Alzheimer's Disease
HSMN NewsFeed - 19 Mar 2007
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting
HSMN NewsFeed - 6 Mar 2007
Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program
Applied NeuroSolutions Hires Top Ranked Analyst, Ryan Rauch, to Direct its Investor Relations Program
HSMN NewsFeed - 5 Mar 2007
Siemens Medical Solutions Collaborates with Wyeth to Advance Development of New Alzheimer's Therapies
Siemens Medical Solutions Collaborates with Wyeth to Advance Development of New Alzheimer's Therapies
HSMN NewsFeed - 5 Mar 2007
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
Myriad Presents Additional Flurizan(TM) Phase 2 Study Data Demonstrating Benefit in Alzheimer's Patients
HSMN NewsFeed - 28 Feb 2007
EPIX Pharmaceuticals Files Formal Appeal for Vasovist(TM) with the Center for Drug Evaluation and Research
EPIX Pharmaceuticals Files Formal Appeal for Vasovist(TM) with the Center for Drug Evaluation and Research
HSMN NewsFeed - 21 Feb 2007
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
HSMN NewsFeed - 19 Jan 2007
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
Bayer Schering Pharma to Develop New Imaging Compounds for Detection of Neurodegenerative Diseases
HSMN NewsFeed - 11 Jan 2007
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
FDA Clears Humanetics' IND Filing to Commence Clinical Studies on New Radiation Countermeasure
HSMN NewsFeed - 10 Jan 2007
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
Panacea Pharmaceuticals Appoints Pamela Harris, MD, Vice President Medical and Clinical Affairs
HSMN NewsFeed - 4 Jan 2007
Court Affirms $7 Million in Damages for Innogenetics in Patent Infringement Suit
Court Affirms $7 Million in Damages for Innogenetics in Patent Infringement Suit
HSMN NewsFeed - 3 Jan 2007
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
D-Pharm Announces Positive Phase IIb Trial Results for DP-b99 in Acute Stroke Patients
HSMN NewsFeed - 14 Dec 2006
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
EPIX Pharmaceuticals to File Appeal with the Center for Drug Evaluation and Research for Vasovist(TM)
HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Additional items found! 475
Members Archive contains
475 additional stories matching:
Alzheimer's disease
(Password required)
Alzheimer's disease
(Password required)